INM InMed Pharmaceuticals Inc. Stock Quote

INM [NASD]

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	0.78%	Shs Outstand	14.15M	Perf Week	36.75%
Market Cap	124.54M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	25.83%	Shs Float	-	Perf Month	-13.94%
Income	-	PEG	-	EPS next Q	-0.22	Inst Own	9.05%	Short Float	-	Perf Quarter	-47.86%
Sales	0.57M	P/S	216.71	EPS this Y	34.20%	Inst Trans	-	Short Ratio	0.19	Perf Half Y	-51.45%
Book/sh	1.47	P/B	5.97	EPS next Y	51.00%	ROA	-	Target Price	3.40	Perf Year	-84.42%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	5.82 - 59.25	Perf YTD	-73.13%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-84.07%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	62.09%	ATR	1.46
Employees	13	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	55.64	Volatility	33.39% 16.65%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	46.96	Prev Close	8.80
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	35.45K	Price	9.44
Recom	3.00	SMA20	13.00%	SMA50	-2.38%	SMA200	-56.88%	Volume	330,635	Change	7.25%

Aug-23-22 05:00PM	InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria GlobeNewswire
Aug-09-22 07:30AM	InMed Announces Changes to its Board of Directors GlobeNewswire
Jul-25-22 07:30AM	InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa GlobeNewswire
Jul-18-22 07:30AM	InMed Announces Appointment of Chief Operating Officer GlobeNewswire
Jul-12-22 11:33PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance GlobeNewswire
Jun-14-22 07:30AM	InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions GlobeNewswire
Jun-09-22 07:30AM	InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector GlobeNewswire
Jun-06-22 06:49PM	InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Jun-02-22 08:00AM	InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules GlobeNewswire -6.04%
May-13-22 08:45AM	InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update GlobeNewswire
May-05-22 07:30AM	InMed to Supply Rare Cannabinoids to Radicle Sciences Radicle Energy Study to Assess the Health Effects of THCV GlobeNewswire -8.36%
May-03-22 12:00PM	InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids ACCESSWIRE
Apr-28-22 07:30AM	InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert GlobeNewswire +8.15%
Apr-21-22 07:30AM	InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector GlobeNewswire
Apr-19-22 07:30AM	InMed to Participate in Upcoming Investor Conferences in April and May 2022 GlobeNewswire
Mar-17-22 07:30AM	InMed Announces Management Changes GlobeNewswire +5.80%
Mar-08-22 07:30AM	InMed to Present at the 34th Annual Roth Conference GlobeNewswire -7.05%
Feb-16-22 07:30AM	InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT ACCESSWIRE
Feb-15-22 07:30AM	InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica GlobeNewswire
Feb-14-22 08:45PM	InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:34PM	InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update GlobeNewswire
Feb-10-22 07:30AM	InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022 GlobeNewswire
Jan-19-22 07:30AM	InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector GlobeNewswire +6.61%
Jan-05-22 07:30AM	InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook GlobeNewswire
Dec-30-21 07:30AM	Registration Now Open For Tribe Publics Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMeds Management Team On January 6, 2022 GlobeNewswire
Dec-20-21 07:30AM	InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma GlobeNewswire
Dec-17-21 07:57PM	InMed Announces Results of 2021 Annual General Meeting GlobeNewswire
Nov-23-21 07:30AM	InMed Pharmaceuticals to Participate in Cowens 4th Annual Cannabis Conference GlobeNewswire
Nov-18-21 12:23PM	44 Stocks Moving In Thursday's Mid-Day Session Benzinga -8.72%
Nov-17-21 08:25AM	InMed Pharmaceuticals (INM): Progress Across the Business ACCESSWIRE +39.29%
Nov-10-21 09:05AM	InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:30AM	InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update GlobeNewswire
Nov-03-21 07:30AM	InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid GlobeNewswire
Oct-22-21 12:48PM	35 Stocks Moving In Friday's Mid-Day Session Benzinga -15.18%
07:32AM	26 Stocks Moving in Friday's Pre-Market Session Benzinga
Oct-18-21 07:02AM	21 Stocks Moving in Monday's Pre-Market Session Benzinga +9.29%
Oct-15-21 11:14AM	InMed Pharmaceuticals Inc. Announces Completion of BayMedica Acquisition Benzinga -9.68%
Oct-13-21 04:30PM	InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids GlobeNewswire
Sep-30-21 08:46AM	4 Penny Stocks Insiders Are Buying Benzinga
07:30AM	InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa GlobeNewswire
Sep-24-21 12:31PM	InMed Pharmaceuticals Inc. Releases FY 2021 Financial Report And Corporate Update Benzinga
07:30AM	InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update GlobeNewswire
Sep-20-21 07:50AM	InMed Pharmaceuticals (INM): Acquiring BayMedica ACCESSWIRE
Sep-17-21 01:14PM	InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021 GlobeNewswire
07:30AM	InMed Pharmaceuticals and BayMedica Participating in Tribe Publics Webinar "Accelerating The Commercialization of Rare Cannabinoids" GlobeNewswire
Sep-13-21 11:47AM	InMed Pharmaceuticals Inc. Enters Agreement For 'Transformative' Acquisition Of Leading Manufacturer Of Rare Cannabinoids Benzinga
09:59AM	InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids Benzinga
08:43AM	Cannabis Industry Investor Presentations Now Available for On-Demand Viewing CNW Group
07:32AM	Cannabis Industry Investor Presentations Now Available for On-Demand Viewing PR Newswire
07:30AM	InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids GlobeNewswire
Sep-09-21 07:18PM	InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-07-21 04:04PM	InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th PR Newswire
Sep-03-21 08:35AM	Cannabis Executives Present: Cannabis Investor Conference September 8th & 9th CNW Group
Sep-02-21 08:35AM	Cannabis Industry Investor Conference: Company Executives Present September 8th & 9th PR Newswire
Aug-25-21 01:27PM	InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production Of Rare Cannabinoids At Pharmaceutical Levels Benzinga
Aug-12-21 12:00PM	InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference GlobeNewswire
Jul-02-21 04:15PM	InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules GlobeNewswire
Jun-29-21 07:00AM	InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids GlobeNewswire +9.46%
07:00AM	InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules GlobeNewswire
Jun-28-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire
Jun-22-21 12:29PM	InMed Pharmaceuticals to Webcast Live at Life Sciences Investor Forum June 24th GlobeNewswire
Jun-21-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021 GlobeNewswire
Jun-17-21 07:30AM	InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn in Advance of Commercial Scale Production GlobeNewswire
Jun-15-21 06:41AM	Is InMed Pharmaceuticals Inc. (INM) A Good Stock To Buy Now? Insider Monkey
Jun-09-21 11:30AM	InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference GlobeNewswire
May-13-21 09:15AM	InMed Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE -16.86%
07:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results GlobeNewswire
May-06-21 07:30AM	InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results GlobeNewswire
May-04-21 07:30AM	InMed to Present at Canaccord Genuitys 5th Annual Global Cannabis Conference on May 11th, 2021 GlobeNewswire
Apr-28-21 07:30AM	InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa GlobeNewswire +11.54%
Apr-27-21 07:30AM	InMed Pharmaceuticals Announces Voluntary Delisting from TSX GlobeNewswire -5.06%
Apr-26-21 07:30AM	InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn GlobeNewswire +24.04%
Mar-17-21 02:49PM	Ontario Lottery and Gaming Corporation - MidDay lottery winning numbers - March 17, 2021 CNW Group
Mar-03-21 06:00PM	InMed to Present at Virtual Conferences in March 2021 GlobeNewswire
Feb-26-21 08:00AM	IIROC Trading Halt - TTO.H CNW Group
Feb-16-21 07:30AM	InMed Announces Closing of US$4.5 Million Private Placement CNW Group
Feb-11-21 09:30AM	InMed Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE +6.15%
07:30AM	InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results PR Newswire
07:30AM	InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results CNW Group
Feb-08-21 07:04AM	Transnetyx Announces Acquisition of BrainBits® CNW Group
Feb-05-21 09:00PM	InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results PR Newswire -9.39%
12:15PM	InMed Pharmaceuticals Stock Drops After It Presses Capital Raise Button Benzinga
09:53AM	IIROC Trade Resumption - IN CNW Group
09:37AM	IIROC Trading Halt - IN CNW Group
09:34AM	InMed Announces US$4.5 Million Private Placement PR Newswire
09:34AM	InMed Announces US$4.5 Million Private Placement CNW Group
Feb-02-21 07:00AM	Orford Completes the Inaugural Exploration Program on its Joutel Properties. Next program to Begin Mid-February CNW Group
Feb-01-21 05:00AM	February is Heart Month, and after nearly 70 years, Heart & Stroke's signature fundraiser, the door-to-door Canvass goes 100% online CNW Group
Jan-26-21 08:00AM	Mackenzie Investments ETF Report: 2020 Was a Record-Breaking Year for Canadian ETF Industry CNW Group
Jan-19-21 02:00PM	InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe PR Newswire
Jan-18-21 07:00AM	Is InMed Pharmaceuticals (TSE:IN) In A Good Position To Invest In Growth? Simply Wall St.
Jan-08-21 07:30AM	InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects PR Newswire +6.33%
07:30AM	InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects CNW Group
Jan-05-21 04:52PM	InMed to Participate at Virtual Conferences in January 2021 PR Newswire
Dec-11-20 07:00AM	/R E M I N D E R -- Media Advisory - Prime Minister's itinerary for Friday, December 11, 2020/ CNW Group
Nov-25-20 07:30AM	InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects PR Newswire
Nov-24-20 08:00PM	InMed Announces Election of Directors PR Newswire
Nov-18-20 07:30AM	InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics PR Newswire +7.29%
07:30AM	InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics CNW Group

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAMS ERIC A	President & CEO	Apr 14	Buy	0.89	14,160	12,659	59,003	Apr 18 11:46 AM
ADAMS ERIC A	President & CEO	Apr 13	Buy	0.85	8,560	7,276	44,843	Apr 13 09:43 PM
COLWILL BRUCE	CFO	Jan 24	Buy	1.09	5,000	5,438	11,515	Jan 24 02:02 PM
Johnson Shane Aaron	SVP, GM of BayMedica LLC	Jan 06	Buy	1.26	8,500	10,710	304,595	Jan 06 06:40 PM
Johnson Shane Aaron	SVP, GM of BayMedica LLC	Dec 30	Buy	1.33	8,093	10,736	296,095	Dec 30 07:22 PM
Johnson Shane Aaron	SVP, GM of BayMedica LLC	Nov 15	Buy	1.37	5,000	6,845	288,002	Nov 15 03:33 PM
ADAMS ERIC A	President & CEO	Sep 29	Buy	1.73	8,800	15,224	36,283	Sep 30 01:39 PM
ADAMS ERIC A	President & CEO	Sep 28	Buy	1.75	11,400	19,984	27,483	Sep 29 02:00 PM
COLWILL BRUCE	CFO	Sep 28	Buy	1.77	5,000	8,840	6,515	Sep 29 01:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience